HOLON, Israel, June 3, 2019 /PRNewswire/ -- Compugen
Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy
company and leader in predictive target discovery, today announced
that its ongoing Phase 1 clinical trial evaluating COM701, a
first-in-class therapeutic antibody targeting PVRIG, was featured
in a trial-in-progress poster at the 2019 ASCO Annual
Meeting in Chicago, IL.
In a poster (Abstract #TPS2657), titled "A phase I study
evaluating COM701 in patients with advanced solid tumors," the
Company reported that the sixth patient dose cohort of COM701
monotherapy has been completed and that no dose-limiting toxicities
were observed in this and prior dose cohorts. Clinical and
laboratory assessment for safety and tolerability are ongoing for
the next higher dose cohort and for earlier dose cohorts.
Furthermore, enrollment in the combination dose escalation of
COM701 and Opdivo® (Nivolumab) is ongoing. The poster is available
on Compugen's website at www.cgen.com.
About the COM701 Phase 1 Study
The Phase 1 open-label clinical trial of COM701 is designed to
assess the safety and tolerability of administering escalating
doses of COM701 monotherapy as well as combination administration
with Bristol-Myers Squibb's Opdivo® in patients
with advanced solid tumors. Additionally, secondary endpoints
include preliminary antitumor activity, pharmacokinetics and
pharmacodynamics of COM701 monotherapy as well as COM701 in
combination with Opdivo in patients with selected tumor types,
including non-small cell lung cancer, ovarian cancer, breast cancer
and endometrial cancer. The Phase 1 study, which is expected
to enroll approximately 140 patients, is currently recruiting in
the United States. Additional
information is available at
www.clinicaltrials.gov (NTC03667716).
About Compugen
Compugen is a clinical-stage, therapeutic discovery and
development company utilizing its broadly applicable computational
discovery platforms to identify novel drug targets and develop
first-in-class therapeutics in the field of cancer immunotherapy.
The Company's therapeutic pipeline consists of immuno-oncology
programs against novel drug targets it has discovered
computationally, including T cell immune checkpoints and other
early-stage immuno-oncology programs focused largely on myeloid
targets. Compugen's business model is to enter into collaborations
for its novel targets and related drug product candidates at
various stages of research and development. The Company is
headquartered in Israel with
facilities in South San Francisco,
CA. Compugen's ordinary shares are listed on Nasdaq and the
Tel Aviv Stock Exchange under the ticker symbol CGEN. For
additional information, please visit Compugen's corporate website
at www.cgen.com.
Forward-Looking Statement
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements can be identified by the use of
terminology such as "will," "may," "expects," "anticipates,"
"believes," "potential," "plan," "goal," "estimate," "likely,"
"should," "confident," and "intends," and describe opinions about
possible future events. These forward-looking statements involve
known and unknown risks and uncertainties that may cause the actual
results, performance or achievements of Compugen to be materially
different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Among
these risks: Compugen's business model is substantially dependent
on entering into collaboration agreements with third parties and
Compugen may not be successful in generating adequate revenues or
commercializing aspects of its business model. Moreover, the
development and commercialization of therapeutic candidates involve
many inherent risks, including failure to progress to clinical
trials or, if they progress to or enter clinical trials, failure to
advance through clinical development or receive regulatory
approval. These and other factors, including the ability to finance
the Company, are more fully discussed in the "Risk Factors" section
of Compugen's most recent Annual Report on Form 20-F as filed with
the Securities and Exchange Commission (SEC) as well as other
documents that may be subsequently filed by Compugen from time to
time with the SEC. In addition, any forward-looking statements
represent Compugen's views only as of the date of this release and
should not be relied upon as representing its views as of any
subsequent date. Compugen does not assume any obligation to update
any forward-looking statements unless required by law.
Company contact:
Elana
Holzman
Director, Investor Relations and Corporate Communications
Compugen Ltd.
Email: elanah@cgen.com
Tel: +972(3)765-8124
Investor Relations contact:
Burns McClellan, Inc.
Lee Roth
Email: lroth@burnsmc.com
Tel: +1-212-213-0006
View original
content:http://www.prnewswire.com/news-releases/compugen-presents-update-on-com701-phase-1-trial-at-the-2019-asco-annual-meeting-300860456.html
SOURCE Compugen Ltd.